Oncology | Drugs in Discovery | Pipeline Prospector

Sanofi

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Contact Supplier

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: UNIV TX MD ANDERSON

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 14, 2020

Details:

The alliance will combine MD Anderson’s clinical trials infrastructure and Sanofi’s pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

HiFiBiO Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

Lead Product(s): Anti-AML specific antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Kite Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 03, 2020

Details:

Through this collaboration, HiFiBiO will use its proprietary technology platforms to identify novel AML targets and anti-AML specific antibodies for Kite’s use in cell therapies.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Cancer Research Uk and AstraZeneca’s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody

Lead Product(s): C0021158

Therapeutic Area: Oncology Product Name: C0021158

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

ARG2 targets and destroys L-arginine, an amino acid critical for immune cells to fight diseases such as cancer, as well as infections.

Harbour BioMed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Lead Product(s): Antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Vir Biotechnology

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 24, 2020

Details:

HBM will leverage its tools in next-generation technologies including its transgenic Harbour Mice® platforms to generate antibodies for the collaboration.

Tango Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: $6,295.0 million Upfront Cash: $125.0 million

Deal Type: Collaboration August 17, 2020

Details:

Under the expanded multi-year collaboration, Tango will continue to leverage its proprietary, CRISPR-enabled functional genomics target discovery platform to identify novel immune evasion targets. The number of targets covered will expand from five to 15.

Matterhorn Biosciences

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Versant Ventures Launches Matterhorn Biosciences

Lead Product(s): T cell therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Versant Ventures

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Funding August 05, 2020

Details:

Matterhorn Biosciences is developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins.

Twist Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

Lead Product(s): Bispecific antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Seismic Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 04, 2020

Details:

Twist Biopharma will use Hyperimmune Libraries, two fully human antibody libraries focused on the heavy chain complementary determining region 3 (CDR3) loop diversity involved in antigen recognition, to identify antibodies that bind to the specified immuno-oncology targets.

PMV Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

PMV Pharma Raises $70M for Tumor Suppressor Programs

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Avoro Capital

Deal Size: $70.0 million Upfront Cash: Undisclosed

Deal Type: Series D Financing August 03, 2020

Details:

The proceeds from the financing provides PMV Pharma with the resources to expand its pipeline and to potentially advance multiple p53 therapies into the clinic.

Schrodinger

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Viva Biotech

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 28, 2020

Details:

Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.

Kobe University

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Lynk Pharmaceuticals Ink Licensing Agreements with Kobe University and RIKEN Research Institute to develop RAS inhibitors with a New MOA

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Lynk Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement July 27, 2020

Details:

Lynk Pharmaceuticals will utilize its medicinal chemistry and drug design expertise to develop RAS inhibitors with desirable properties to target a broader range of undruggable RAS onco-drivers and ultimately develop the compounds for clinical use.

Find

Find Novel Oncology Drugs in Discovery

Discovery

Product Type

Companies

Sanofi

Sanofi, MD Anderson Join Forces to Ramp up Cancer R&D

HiFiBiO Therapeutics

Kite and Hifibio Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia

AstraZeneca PLC

Cancer Research Uk and AstraZeneca’s New Antibody Maturation Technique Yields High-Affinity Arginase 2 Antibody

Harbour BioMed

Harbour BioMed Collaborates with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

Tango Therapeutics

Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration

Matterhorn Biosciences

Versant Ventures Launches Matterhorn Biosciences

Twist Bioscience

Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies

PMV Pharma

PMV Pharma Raises $70M for Tumor Suppressor Programs

Schrodinger

Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets

Kobe University

Lynk Pharmaceuticals Ink Licensing Agreements with Kobe University and RIKEN Research Institute to develop RAS inhibitors with a New MOA